We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Homology Medicines raises $83.5mm in Series B round

Aug 2017

Executive Summary

Homology Medicines Inc. (gene editing and gene therapy technologies) raised $83.5mm in its Series B financing round led by Deerfield Management. New investors Fidelity Management and Research, HBM Healthcare Investments, Maverick Ventures, Novartis AG, Rock Springs Capital, Vida Ventures, Vivo Capital (also adds a board seat), and Alexandria Venture Investments joined repeat backers 5AM Ventures, ARCH Venture Partners, and Temasek. The company previously raised $44mm in a Series A round back in May 2016. Homology expects to use the proceeds to advance its lead candidate (currently in preclinical IND-enabling studies for an inborn error of metabolism disease) and to support continued work on its AMEnDR (AAV-Mediated Editing by Direct Homologous Recombination) technology for rare genetic diseases.

Deal Industry

Biotechnology

Gene Therapy, Cell Therapy

Pharmaceuticals

Deal Status

Final

Deal Type

Financing

Private Placement

Already a Strategic Transactions subscriber?You have access to the full deal record through your subscription

Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?

Related Companies

Not all deals are the same. Rely on the pioneer in deal making intelligence – Strategic Transactions for analyzing and tracking healthcare deals. With over 20 years of global M&A, financing, and alliance activity – Strategic Transactions is the premium source that top pharmaceutical firms, PLUS leaders in medical devices, diagnostics, finance, and consulting turn to for the best available intelligence for deals in the industry.